Better Health for All

The company's core business is focused on developing novel therapies for rare, chronic, and infectious diseases with high unmet needs, including NTM lung disease and neglected tropical diseases like Chagas disease, indicating an entire business devoted to health improvement.

For its Global Access Products, the company has agreed to a maximum price capped at cost of sales plus 25%, and implements tiered pricing based on buyer type and geographic location to reflect the price sensitivity of low-income patients.

Fair Pay & Worker Respect

The provided articles do not contain specific, concrete data points for any of the Fair Pay & Worker Respect KPIs. While some articles state that no regulatory actions, violations, fines, or compliance issues are mentioned within their content,

this is not considered a concrete data point for scoring the 'labor_violation_incidents' KPI, as it refers to the absence of information in the articles rather than a definitive statement about the company's record. Information regarding living wage, CEO to median pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, voluntary turnover, insecure contracts, or health insurance coverage is not available.

Fair Trade & Ethical Sourcing

No specific data regarding ANTX.US's fair trade and ethical sourcing practices, supplier certifications, audit frequencies, incidents of forced or child labor, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk, or supplier diversity spend was found in the provided articles.

The articles discuss general industry challenges and best practices but do not offer company-specific quantitative metrics for ANTX.US.

Honest & Fair Business

AN2 Therapeutics has a confidential and anonymous financial concern hotline and a secure web form for reporting complaints regarding accounting, internal accounting controls, or auditing matters.

The Audit Committee oversees and reviews the company's Whistleblower Policies and establishes procedures for confidential and anonymous submissions. The company made a non-cash adjustment of $0.6 million to correct stock-based compensation expense for the first and second quarters of 2025, which was not material to previously issued financial statements. The company identified material weaknesses in its internal control over financial reporting. Pomerantz LLP is investigating claims of securities fraud or other unlawful business practices against AN2 and its officers/directors, triggered by a 74.50% stock price drop on February 12, 2024, following a voluntary pause in a Phase 3 clinical trial due to potentially lower than expected efficacy. The Nominating and Corporate Governance Committee charter, effective November 15, 2024, states that each committee member shall be free from any relationship that would interfere with independent judgment, as determined by the Board, in accordance with Nasdaq requirements. The company has an Anti-Corruption Policy, which the Audit Committee periodically reviews and monitors for compliance. The Global Health Agreement also contains anti-corruption requirements.

Kind to Animals

The company undertakes pre-clinical studies on animals to examine the safety profile of its medications.

Its lead product candidate, epetraborole, has demonstrated efficacy in animal models of NTM infection. There is no evidence that the company employs non-animal testing methods for product safety and efficacy. The company's policy involves animal testing for pre-clinical studies.